Literature DB >> 26833982

Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection.

Jae Hoon Moon1, June Young Choi2, Woo-Jin Jeong3, Soon-Hyun Ahn3, Won Woo Lee4, Kyoung Min Kim1, Sung Hee Choi1, Soo Lim1, Young Joo Park5, Ka Hee Yi6, Do Joon Park5, Hak Chul Jang1.   

Abstract

OBJECTIVE: We investigated the value of the stimulated thyroglobulin (Tg) level at the time of recombinant human thyrotropin (rhTSH)-aided remnant ablation for predicting disease status 1 year later in patients with DTC who underwent total thyroidectomy with central neck dissection (CND). DESIGN, SETTING, AND PARTICIPANT: This was a prospective observational study of 253 consecutive patients with DTC who underwent rhTSH-aided RAI ablation after total thyroidectomy and prophylactic CND. Patients with evidence of initial distant metastasis or positive Tg antibodies were excluded. MAJOR OUTCOME MEASURE: We compared rhTSH-stimulated Tg level at RAI ablation according to the disease status at 1 year and evaluated optimal cut-off value of rhTSH-stimulated Tg. Binary logistic regression analysis was performed to investigate the independent predictive factors for disease status 1 year after ablation.
RESULTS: Among study participants, 228 (90·1%) were considered disease free at 1 year after remnant ablation. Patients with persistent or recurrent disease were more likely to be aged ≥45 years, and to have N1b stage, TNM stage III or IV, and higher rhTSH-stimulated Tg level at RAI ablation. The optimal cut-off of rhTSH-stimulated Tg for predicting persistent or recurrent disease was 1·79 ng/ml, with a negative predictive value of 99·5%. A serum rhTSH-stimulated Tg level ≥1·79 at the time of ablation was independently associated with persistent or recurrent disease 1 year later. N1b stage tended to be associated with persistent or recurrent disease.
CONCLUSION: A low stimulated serum Tg level at rhTSH-aided RAI ablation may be a favourable prognostic marker in the setting of prophylactic CND.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26833982     DOI: 10.1111/cen.13029

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  3 in total

1.  Comparison of Thyroglobulin Measurements Using Three Different Immunoassay Kits: A BRAMHS Tg-Plus RIA Kit, a BRAMHS hTg Sensitive Kryptor Kit, and a Beckman Coulter ACCESS Immunoassay Kit.

Authors:  Mijin Kim; Min Ji Jeon; Won Gu Kim; Jong Jin Lee; Jin Sook Ryu; Eun Jung Cho; Dae Hyun Ko; Woochang Lee; Sail Chun; Won Ki Min; Tae Yong Kim; Young Kee Shong; Won Bae Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2016-08-02

2.  Relation between surgical oncologic quality indicators for papillary thyroid cancer.

Authors:  Nicole Mak; Kristen Van Esch; Sam M Wiseman
Journal:  Can J Surg       Date:  2022-10-04       Impact factor: 2.840

3.  Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer.

Authors:  Aleksandra Ledwon; Ewa Paliczka-Cieślik; Aleksandra Syguła; Tomasz Olczyk; Aleksandra Kropińska; Agnieszka Kotecka-Blicharz; Kornelia Hasse-Lazar; Aneta Kluczewska-Gałka; Barbara Jarząb; Daria Handkiewicz-Junak
Journal:  Ann Nucl Med       Date:  2021-08-07       Impact factor: 2.668

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.